ARCHIVES

Retrospective Data Clean-up Can’t Help C225 Phase II Trial; Protocol Far Too “Fuzzy”

This article is from The Cancer Letter archive.

Vol. 28 No. | March 8, 2002

Download PDF Visit The Full Archive

Related Articles

After Congressional Inquiry, NCI Posts Ambiguous Statement On Abortion And Breast Cancer Risk

December 13, 2002

NCI Intends To Extend OSCC Two More Years

October 3, 1986

Addition of Cobimetinib Boosts PFS in BRAF Mutation-Positive Patients in Phase III Trial

July 25, 2014

NTP Release Third Report On Carcinogens

January 13, 1984

NCI Cooperative Group Clinical Trials Approved

February 26, 2010

Avastin Vote Puts Focus On FDA Criteria In First-Line Metastatic Breast Cancer: Is PFS Good Enough?

December 14, 2007